slide1
Download
Skip this Video
Download Presentation
Three Traps to Avoid & Bioinformatics Advantage

Loading in 2 Seconds...

play fullscreen
1 / 9

Three Traps to Avoid & Bioinformatics Advantage - PowerPoint PPT Presentation


  • 86 Views
  • Uploaded on

Three Traps to Avoid & Bioinformatics Advantage. 1.) In the Discovery Phase Its ok to “Fish” for significant relationships in your data (i.e. look at correlations across all my variables and then report the significant ones that you find). .

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Three Traps to Avoid & Bioinformatics Advantage' - etan


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
three traps to avoid bioinformatics advantage
Three Traps to Avoid

&

Bioinformatics Advantage

slide3

1.) In the Discovery Phase

Its ok to “Fish” for significant relationships in your data (i.e. look at correlations across all my variables and then report the significant ones that you find).

slide4

With alpha=0.05, after 20 correlations you can expect to make a spurious correlation. Data Mining is a bioinformatics tool, you just need to know the rules.

slide5
2.) In an Early Phase Trial

I can only afford to have 25 patients in this first trial, I don’t need a “power” calculation.

slide6

Even when you know how many patients you can afford, changing the design slightly or balancing the study arms differently can increase your ability to observe true differences.

Model various scenarios to optimize your design.

slide7
3.) In a Phase 3 Trial

Having “enough” patients in each arm is most important to demonstrate efficacy and safety.

slide8
Genotyping and biomarkers can identify the appropriate patient population to:

Reduce Safety Risks and

Improve Efficacy

slide9

A Boutique Statistical Consulting Firm

Serving Industry and Academia in Clinical Trials and Drug Discovery

ad